Genetic Variants of Annexin A2 and Cryptogenic Stroke

Not Applicable

Not yet recruiting

• Conditions: Annexin A2; Stroke; Genetic Variants of Host; Fibrinolysis
• Interventions: Biological: blood withdrawal

• Registration Number: NCT06880107
• Lead Sponsor: Centre Hospitalier Universitaire, Amiens

Brief Summary

Stroke is the third most common cause of death in developed countries. Various mechanisms of ischemic stroke exist. However, in young population, in a third of cases, the cause of a stroke cannot be determined despite an extensive evaluation. Many studies have highlighted the link between stroke and fibrinolysis. Genetic variants of tPA and PAI-1 genes have been suggested to be the risk factors for stroke.

ANXA2 plays a pivotal role in plasmin generation and fibrinolysis. Several studies showed the role of ANXA2 and S100A10 subunits in regulation of fibrinolysis in vivo. Recently, the efficacy of recombinant ANXA2 for fibrinolytic therapy in a rat embolic stroke has been demonstrated. Some single nucleotide polymorphisms in ANXA2 gene could be associated with increased risk of stroke in sickle cell disease.

Therefore, these data invite us to test hypothesis that genetic variants of ANXA2 gene could be associated with ischemic stroke.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-03
• Study First Submitted: 2025-03-11
• Study First Submitted QC: 2025-03-11
• Study First Posted: 2025-03-17
• Last Update Submitted: 2025-05-06
• Last Update Posted: 2025-05-11
• Study Start: 2025-07
• Primary Completion: 2027-04
• Study Completion: 2027-04

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

• Completed ischemic stroke defined as a rapidly developing focal neurologic deficit with no apparent cause other than a vascular origin that persisted beyond 24 hours in surviving patients
• Age from 18 years old

Exclusion Criteria

• Transient ischemic attack
• Pregnancy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
cryptogenic stroke	blood withdrawal	cryptogenic stroke
ischemic stroke	blood withdrawal	ischemic stroke
control subjects	blood withdrawal	control subjects

Primary Outcome Measures

Name	Time	Method
genetic variants of ANXA2	day 1
genetic variants of S100A10	day 1

Secondary Outcome Measures

Name	Time	Method
blood ANXA2 concentration	day 1
blood S100A10 concentration	day 1
concentration of Autoantibodies directed against ANXA2	day 1
concentration of S100A10 directed against ANXA2	day 1

Trial Locations

Locations (1)

CHRU Amiens; 🇫🇷 Amiens, France